Familial hypercholesterolaemia: identification and management
Status Complete
Anticipated publication date August 2008
Process CG
Topic area
  • Endocrine, nutritional and metabolic

Email enquiries


Key events during the development of the guidance

Date Update
24 December 2003 The remit (see link below) was received from the Department of Health and the Welsh Assembly Government in October 2003 as part of the Institute's 9th wave work programme.
5 April 2004 Patient Involvement Lead added.
24 August 2004 Executive lead updated.
10 July 2006 The draft scope (see link below) is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed above, by the deadline shown.
8 September 2006 Guidelines Coordinator changed to Bijal Chandarana
4 December 2006 List of stakeholders updated.
10 January 2007 Communications manager changed
11 January 2007 Expected date of issue changed to August 2008
1 February 2007 GDG membership list added.
8 February 2007 The scope (see link below) defines what aspects of care are covered by the guideline and to whom it applies.
13 February 2007 Table of comments on the draft scope published
15 July 2008 It was stated in the initial scope that TA94: Statins for the prevention of cardiovascular disease would be incorporated. It was found that the TA was not relevant to the FH population covered in the guideline. The scope has been amended.